Kevin Skelsey, MD
Ophthalmology · Lees Summit, MONPI 1982696134
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,210 of the $12,218 with a category attached, or 83.6%. It is spread thinly across 32 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations.
Across 382 payments — averaging $31.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$3K
- AbbVie$2K
- Johnson & Johnson Surgical Vision, Inc.$1K
- Glaukos Corporation$1K
- Sun Pharmaceutical Industries Inc.$599
- Bausch & Lomb, A Division Of Bausch Health US, LLC$570
- plus $4K from 26 others
What the payments were for
- Speaking & faculty fees$260%
- Travel & lodging$1,93216%
- Food & beverage$10,21084%
- Education$50%
- Gifts$450%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 41 | $2,606 |
| AbbVie(2 entities) | 117 | $2,401 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $1,167 |
| Glaukos Corporation | 24 | $1,123 |
| Sun Pharmaceutical Industries Inc. | 23 | $599 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 29 | $570 |
| Alcon | 24 | $525 |
| Novartis | 15 | $438 |
| Mallinckrodt Hospital Products Inc. | 15 | $396 |
| Aerie Pharmaceuticals, Inc. | 14 | $380 |
| Rayner Intraocular Lenses Limited | 3 | $324 |
| The Cameron-ehlen Group, Inc. | 9 | $316 |
| Oyster Point Pharma, Inc. | 13 | $250 |
| Rxsight Inc | 6 | $183 |
| Dompe US, Inc. | 5 | $126 |
| Sight Sciences, Inc. | 7 | $118 |
| Alcon Research LLC | 2 | $109 |
| Tarsus Pharmaceuticals, Inc. | 4 | $105 |
| Kala Pharmaceuticals, Inc. | 5 | $97 |
| Thea Pharma Inc. | 4 | $75 |
| Amgen(2 entities) | 3 | $67 |
| ANI Pharmaceuticals, Inc. | 2 | $50 |
| AstraZeneca | 1 | $26 |
| Carl Zeiss Meditec, Inc. | 2 | $26 |
| Eyevance Pharmaceuticals LLC | 1 | $22 |
| Harrow Eye, LLC | 1 | $19 |
| Ivantis, Inc | 1 | $19 |
| Ocular Therapeutix, Inc. | 1 | $19 |
| Biotissue Holdings Inc. | 1 | $18 |
| Trevena, Inc. | 1 | $16 |
| Eyepoint US, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- enVista Aspire IOL$1,254
- TENEO$1,254
- STELLARIS ELITE$1,254
- Tecnis 1-piece IOL$1,084
- Tecnis 3-piece IOL$1,084
- Tecnis Symfony IOL$1,084
- Tecnis Symfony Toric IOL$1,084
- iDoseTR$309
- RayOne EMV$267
- RayOne Spheric$267
- RayOne Aspheric$267
- LUMIGAN$236
- STELLARIS$176
- iStent Infinite$148
- Clareon PanOptix Pro$143
- OMIDRIA$140
- ACTHAR$132
- CEQUA$125
- RESTASIS$125
- Rhopressa$122
How this compares
$12,218 in reported general payments places this provider in the 85th percentile of 286 ophthalmology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 222 | $115,843 |
| RestasisCyclosporine | 46 | $60,569 |
| CombiganBrimonidine Tartrate/Timolol | 78 | $37,453 |
| Alphagan PBrimonidine Tartrate | 62 | $29,386 |
| XiidraLifitegrast | 20 | $23,240 |
| RocklatanNetarsudil Mesylat/Latanoprost | 33 | $15,021 |
| Prednisolone Acetate | 319 | $10,136 |
| VyzultaLatanoprostene Bunod | 18 | $9,688 |
| Latanoprost | 568 | $8,851 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 38 | $8,096 |
| Brimonidine Tartrate | 45 | $6,794 |
| Cyclosporine | 12 | $6,091 |
| RhopressaNetarsudil Mesylate | 12 | $5,453 |
| TafluprostTafluprost/Pf | 11 | $1,898 |
| Travoprost | 13 | $1,801 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $2,401 | $243,251408 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $2,606 | $32,92938 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $380 | $20,47445 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 286 ophthalmology providers in Missouri.
Other ophthalmology in Lees Summit
- Steven SilversteinKansas City$872K
- Ranjan MalhotraSaint Louis$809K
- Nancy HolekampChesterfield$768K
- Jay PeposeChesterfield$516K
- Gregg BerdySaint Louis$360K
- Joseph GiraDes Peres$174K
- Joseph TauberKansas City$174K
- Jella AnColumbia$166K
- Shachar TauberSpringfield$150K
- Rajendra ApteSaint Louis$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.